摘要
目的探讨新辅助化疗在经尿道膀胱肿瘤电切术中的临床应用价值及对预后的影响。方法将我院收治的77例浅表性膀胱肿瘤患者按照随机分层分组法分为观察组和对照组,对照组经尿道电切术后行膀胱灌注化疗,观察组在此基础上行术前膀胱灌注化疗,观察两组毒副反应及并发症发生情况,随访3年,观察两组患者复发情况及尿液中肿瘤标志物水平。结果观察组术前血液学及肝肾功能指标与对照组比较差异无统计学意义(P>0.05),观察组不良反应发生率为24.4%(11/45),术后并发症发生率为11.1%(5/45),对照组不良反应发生率为28.1%(9/32),术后并发症发生率为12.5%(4/32),两组比较差异无统计学意义(P>0.05);随访3年,观察组复发率及尿液中肿瘤标志物含量均显著优于对照组,两组比较差异有统计学意义(P<0.05)。结论新辅助化疗能显著降低经尿道膀胱肿瘤电切术患者的复发率,且不增加毒副反应和术后并发症发生率,具有较高的临床应用价值。
Objective To explore the application of neoadjuvant chemotherapy in treatment of patients with superficial bladder cancer and the influence on prognosis.Methods According to a stratified randomization method,77cases of patients with superficial bladder cancer were divided into observation group and control group,control group was given intravesical chemotherapy after surgery,observation group was given preoperative chemotherapy,the incidence of adverse reactions,the incidence of postoperative complications,the recurrence rate and the levels of tumor markers in urine of the two groups were observed.Results There was no significant difference in the preoperative hematological indices,hepatic and renal function between observation group and control group（P〉0.05）,the incidence of adverse reactions of the observation group was 24.4%（11 /45）,the incidence of postoperative complications was11.1%（5 /45）,while they were 28.1%（9 /32）,and 12.5%（4 /32） of control group respectvely,there was no significant difference between the two groups（P〉0.05）;follow-up 3-year,the observation group was significantly better than the control group in the recurrence rate and the levels of tumor markers in urine（P〈0.05）.Conclusion Neoadjuvant chemotherapy can significantly reduce the recurrence rate of transurethral resection in treatment of superficial bladder cancer,but it does not increase the incidence of adverse reactions and the incidence of postoperative complications.
出处
《实用药物与临床》
CAS
2014年第7期875-878,共4页
Practical Pharmacy and Clinical Remedies
关键词
新辅助化疗
电切术
膀胱肿瘤
临床疗效
Neoadjuvant chemotherapy
TURBT
Bladder cancer
Clinical efficacy
